SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Florence Griffith Joyner

PatientFlorence Griffith Joyner
Date of birth1989-12-21
IdentifiersMRN HR-ML033-SYN; SSN (made up) 000-33-2648
Document date2026-05-27
AuthorCeleste Vanterpool, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Three weeks on levetiracetam; neurosurgical opinion; SUDEP and safety counseling. [S]

History of Present Illness

Ms. Griffith Joyner returns three weeks after starting levetiracetam. She has taken every dose. In the first ten days she felt short-tempered and more tired than usual after training; both are easing. She has had no seizure or spell. The neurosurgeon saw her last week and offered complete removal of the cavernous malformation with its hemosiderin rim through a left frontal craniotomy; she has chosen surgery, booked in three weeks. She wears the detection watch at night. She has not driven. She has had no thoughts of self-harm. [S]

ElementDetail
LevetiracetamEvery dose taken; irritability and tiredness easing
SeizuresNone since the flight
NeurosurgeryLesionectomy offered and chosen; booked in three weeks
SafetyDetection watch at night; not driving

Review of Systems

SystemResultFinding
ConstitutionalPositiveMore tired than usual after training, improving
NeurologicalNegativeNo seizures, spells, headache or dizziness
PsychiatricPositiveShort-tempered in the first ten days, easing; sleep normal; PHQ-9 6; no thoughts of self-harm
MusculoskeletalNegativeTraining without injury

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Levetiracetam 500 mg oral tablet, one tablet by mouth twice dailyOne tablet twice dailyOral route2026-05-05activeS
Folic acid 0.4 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-05-05activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-05-27Body height170cmS
2026-05-27Body weight60.8kgS
2026-05-27Body mass index (BMI) [Ratio]21kg/m2S
2026-05-27Systolic blood pressure114mm[Hg]S
2026-05-27Diastolic blood pressure72mm[Hg]S
2026-05-27Heart rate60/minS
2026-05-27Respiratory rate14/minS
2026-05-27Body temperature36.7CelS
2026-05-27Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-05-27Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S

Physical Exam

Vital signs recorded on 2026-05-27; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 60.8 kg; blood pressure 114/72, pulse 60
NeurologicalAlert; speech, strength, coordination and gait normal
PsychiatricCalm and engaged; describes the irritability with insight

Problems

ProblemClinical statusVerificationCodeProvenance
Generalized tonic-clonic seizure on a flight two and a half weeks ago, in a 36-year-old woman who was observed overnight in hospital elsewhere and has had treatment for seizures in the past, records requested; no antiseizure medication now; normal examination today. Evaluated as a new seizure: EEG and MRI of the brain with susceptibility-weighted imaging ordered, neurology (epilepsy) review booked, and no drivingresolvedconfirmed R56.9S — Synthetic presenting problem anchored to her publicly reported seizure on a flight; superseded by the diagnosis at the epilepsy consultation.
Focal epilepsy with structural cause: focal to bilateral tonic-clonic seizure from a left orbitofrontal cavernous malformation, with left frontal epileptiform discharges on EEG; epilepsy under the ILAE 2014 practical definition (an unprovoked seizure with a recurrence risk above 60% from an epileptogenic lesion, and earlier seizures by history); synthetic modern detail linked to her publicly reported seizures and the coroner's findingactiveconfirmed G40.209S — Synthetic seizure type, EEG and classification; the seizures and the cavernous angioma of the left orbital frontal cerebrum are documented (D).
Solitary cerebral cavernous malformation, 1.4 cm, left orbitofrontal cortex, with a hemosiderin rim and an adjacent developmental venous anomaly, no other lesion on susceptibility-weighted imaging (sporadic pattern); no acute hemorrhageactiveconfirmed Q28.3S — Synthetic imaging detail; the coroner reported a congenital cavernous angioma of the left orbital frontal cerebrum (D).

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyMood and behavior on levetiracetam (PHQ-9)Before starting and at each visitCompleted todayPHQ-9 6, from 3: irritability and tiredness on levetiracetam, easing; no thoughts of self-harm
Self-managementSeizure diary and adherenceEach visitCompleted todayNo seizure; every dose taken
ReferralNeurosurgical evaluation of an epileptogenic cavernous malformationWhen a cavernous malformation causes epilepsyUp to dateSeen last week; lesionectomy chosen and booked
Self-managementSUDEP counselingAt diagnosis of epilepsyCompleted todayDiscussed today, three weeks after the diagnosis (deviation recorded at the last visit): what SUDEP is, that tonic-clonic seizures are the main risk factor, and that the best protection is no tonic-clonic seizures, with every dose taken, regular sleep and little alcohol; nocturnal supervision or detection. No harm from the delay: no seizure in the interval. Corrective action: SUDEP added to the clinic's checklist for every new diagnosis of epilepsy
Self-managementNocturnal seizure detectionWhen seizures may occur in sleepCompleted todayWrist-worn detection watch worn every night, alerting a contact she chose
Self-managementDriving restriction and the California physician reportFrom the first seizure until clearedUp to dateNot driving
Self-managementSeizure safety: water, heights, sleep and first aidAt diagnosis and each visitCompleted todayReviewed; she follows the plan
Medication safetyFolic acid and contraceptionEach visitCompleted todayFolic acid taken daily; no pregnancy planned

Goal progress:

Guideline basis: Krumholz A, et al. Evidence-based guideline: Management of an unprovoked first seizure in adults. Neurology 2015;84(16):1705-1713 (PMID 25901057) (2015); Fisher RS, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia 2014;55(4):475-482 (PMID 24730690) (2014); Akers A, et al. Synopsis of Guidelines for the Clinical Management of Cerebral Cavernous Malformations: Consensus Recommendations Based on Systematic Literature Review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel. Neurosurgery 2017;80(5):665-680 (PMID 28387823) (2017); Harden C, et al. Practice guideline summary: Sudden unexpected death in epilepsy incidence rates and risk factors. Neurology 2017;88(17):1674-1680 (PMID 28438841) (2017); Pack AM, et al. Teratogenesis, Perinatal, and Neurodevelopmental Outcomes After In Utero Exposure to Antiseizure Medication: Practice Guideline From the AAN, AES, and SMFM. Neurology 2024;102(11):e209279 (PMID 38748979) (2024); Beniczky S, et al. Automated seizure detection using wearable devices: A clinical practice guideline of the International League Against Epilepsy and the International Federation of Clinical Neurophysiology. Epilepsia 2021;62(3):632-646 (PMID 33666944) (2021); Governor's message returning Senate Bill 357 without signature (physician reporting of disorders characterized by lapses of consciousness remains mandatory under Health and Safety Code section 103900) (2024); Depression and Suicide Risk in Adults: Screening (2023)

Follow-up: Lesionectomy in three weeks. Primary care review about five weeks after surgery. Call at once for another seizure, worsening mood, or any thoughts of self-harm. Next scheduled visit 2026-07-21: five weeks after lesionectomy: recovery, seizure control, return to training. [S]